Ki16425 (CAS 355025-24-0)
See product citations (17)
QUICK LINKS
Ki16425 is a chemical compound recognized for its utility in biological and pharmacological research, particularly in the study of lysophosphatidic acid (LPA) receptors. This compound acts as an antagonist to LPA receptors, which are G protein-coupled receptors involved in various cellular processes. Researchers utilize Ki16425 to understand the signaling pathways mediated by LPA receptors, which include cell proliferation, survival, migration, and cytoskeletal changes. Studies often involve the use of Ki16425 to elucidate the role of LPA signaling in pathological states, including fibrosis and cancer. Additionally, Ki16425 is valuable in investigating the pharmacological effects of LPA receptor modulation, which can influence the development of compounds with potential research applications in cellular physiology and biochemistry.
Ki16425 (CAS 355025-24-0) References
- Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. | Ohta, H., et al. 2003. Mol Pharmacol. 64: 994-1005. PMID: 14500756
- Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1. | Yamada, T., et al. 2004. J Biol Chem. 279: 6595-605. PMID: 14660630
- Protean agonism of the lysophosphatidic acid receptor-1 with Ki16425 reduces nerve growth factor-induced neurite outgrowth in pheochromocytoma 12 cells. | Moughal, NA., et al. 2006. J Neurochem. 98: 1920-9. PMID: 16945108
- Dioleoyl phosphatidic acid increases intracellular Ca2+ through endogenous LPA receptors in C6 glioma and L2071 fibroblasts. | Chang, YJ., et al. 2007. Prostaglandins Other Lipid Mediat. 83: 268-76. PMID: 17499746
- Biological roles of lysophospholipid receptors revealed by genetic null mice: an update. | Choi, JW., et al. 2008. Biochim Biophys Acta. 1781: 531-9. PMID: 18407842
- Synthesis and biological evaluation of optically active Ki16425. | Sato, T., et al. 2012. Bioorg Med Chem Lett. 22: 4323-6. PMID: 22658556
- Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis. | Rancoule, C., et al. 2014. Biochimie. 96: 140-3. PMID: 23639740
- Lysophosphatidic acid receptor 1 antagonist ki16425 blunts abdominal and systemic inflammation in a mouse model of peritoneal sepsis. | Zhao, J., et al. 2015. Transl Res. 166: 80-8. PMID: 25701366
- Antifibrotic effect of lysophosphatidic acid receptors LPA1 and LPA3 antagonist on experimental murine scleroderma induced by bleomycin. | Ohashi, T. and Yamamoto, T. 2015. Exp Dermatol. 24: 698-702. PMID: 25959255
- LPA3-mediated lysophosphatidic acid signaling promotes postnatal heart regeneration in mice. | Wang, F., et al. 2020. Theranostics. 10: 10892-10907. PMID: 33042260
- Molecular mechanisms of cyclic phosphatidic acid-induced lymphangiogenic actions in vitro. | Okuyama, K., et al. 2022. Microvasc Res. 139: 104273. PMID: 34699844
- Activation of the ATX/LPA/LPARs axis induces a fibrotic response in skeletal muscle. | Córdova-Casanova, A., et al. 2022. Matrix Biol. 109: 121-139. PMID: 35385768
- Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid. | Fernandes, MF., et al. 2022. Int J Mol Sci. 23: PMID: 35456981
- Inhibition of ChREBP ubiquitination via the ROS/Akt-dependent downregulation of Smurf2 contributes to lysophosphatidic acid-induced fibrosis in renal mesangial cells. | Kim, D., et al. 2022. J Biomed Sci. 29: 31. PMID: 35538534
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ki16425, 1 mg | sc-221788 | 1 mg | $199.00 | |||
Ki16425, 5 mg | sc-221788A | 5 mg | $612.00 |